AUTHORS
Carlos Hipolito Villa, MD, PhD, Tina Agostini2, Andrew Podd3, Mandy Moelling4, Kimberly Borgwardt5, Kenneth Friedman, MD6, Sandra Haberichter, PhD7, Geoffrey Wool8, Bailey Hutchison9
AFFILIATIONS
1 Versiti, Milwaukee, Wisconsin, United States
2 Versiti, Milwaukee, Wisconsin, United States
3 Versiti, Milwaukee, Wisconsin, United States
4 Versiti, Milwaukee, Wisconsin, United States
5 Versiti, Milwaukee, Wisconsin, United States
6 Versiti, Milwaukee, Wisconsin, United States
7 Versiti, Milwaukee, Wisconsin, United States
8 Versiti, Milwaukee, Wisconsin, United States
9 Versiti, Milwaukee, Wisconsin, United States
ABSTRACT
Background: Current testing guidelines (including CLSI, ISTH, and NASCOLA) for platelet function testing recommend that testing be performed within 4 hours of collection. This recommendation is based on early literature demonstrating that, while reactivity to agonists decreases with time, it is largely preserved up to 4 hours with steeper drops thereafter. Single agonist abnormalities represent the most common abnormal result findings in our lab but are known to frequently represent false positives. We wished to examine the relationship between lumi-aggregometry testing results and sample timing to determine if, within a 4-hour window, the time between sample collection and analysis correlates with the presence of single agonist abnormalities. This information would also help guide the optimal order of testing of individual agonists.
Methods: We reviewed 6 months of platelet function testing by lumi-aggregometry. Our laboratory receives samples from local collections that are delivered via courier, predominantly from a nearby tertiary care children’s hospital. Testing is performed using collagen (2.5 mcg/mL), ADP (10 µM), high dose ristocetin (1.5 mg/mL), arachidonic acid (0.5 mg/mL), and thrombin receptor activating peptide (TRAP, 20 µM) as agonists. Testing is performed on count-adjusted platelet-rich plasma on a Chronolog light-transmission aggregometer with CHRONO-LUME reagent kit for luminometric measurement of dense granule release. All testing is performed with concurrent controls from qualified normal donors. We examined the correlation of maximum aggregation (%) and ATP release (nmol) with time since sample collection and analyzed for significant statistical correlation using Spearman’s coefficient. Our analyses focused on the subset of patient samples with normal results or single agonist abnormalities, as the latter are known to have a high rate of false positivity.
Results: 120 total samples were received for platelet function testing, with 115 samples showing normal results or a single agonist abnormality (the analysis subset). In the analysis subset, samples were analyzed at a mean of 180 minutes post-collection (SD 24 min), with time-to-analysis normally distributed. 87 samples showed normal results for all agonists. 28 samples (23%) showed a single agonist abnormality. The most common abnormality was isolated decreased ATP release in response to ADP agonist (n=26, 22% of the analysis subset). Within a 4-hour testing window, responses to ADP (both aggregation [r=-0.28, p=0.0028] and ATP release [r=-0.37, p<0.0001]) and collagen (ATP release only [r=-0.21, p=0.03]) showed a statistically significant negative association with time since sample collection. The strongest correlation with sample timing was seen for ATP release in response to ADP agonist. Decreased or absent ATP release in response to ADP was more likely to be observed when time-to-analysis was more than 3 hours compared to less than 3 hours (OR 3.98 [1.45, 10.68], p=0.0069).
Conclusions: Even within the recommended 4-hour testing window, increased time between sample collection and analysis may increase the likelihood of single agonist abnormalities, which could represent false positive results. Isolated decreased ATP release in response to ADP appears to have the greatest risk for false positivity due to sample timing. Limitations of the study include measurement of each patient at only a single point in time, and a lack additional clinical information for potential adjudication of abnormal results. The use of data derived from a real-world reference laboratory setting increases the external relevance of the results. To mitigate the risk that sample timing could contribute to false positive results, particularly for ADP agonist, laboratories should emphasize procedures to test samples as early within a 4-hour window as possible, and preferably, prior to 3 hours.
DISCLOSURES
Carlos Hipolito Villa, MD, PhD: No relevant conflicts of interest to declare.